Certara Staff to Demonstrate Drug Development Solutions at Scientific Webinar Series

February 6, 2015

Topics to be presented will include PBPK modeling and simulation, population modeling of e-cigarettes, and artificial intelligence technology for clinical trial transparency.

PRINCETON, NJ –  Feb. 6, 2015 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that senior staff members from Certara will demonstrate their approaches to some of the biggest challenges facing the pharmaceutical industry today in a monthly scientific webinar series starting this month.

“With an arsenal of 98 PhDs and MDs on staff at Certara, we have a brain trust that is unparalleled in its depth and breadth of experience and expertise,” said Certara Head of Consulting Michael Eckstut. “We thought that a webinar series would be a great way to highlight our scientific thought leadership in a format that is readily accessible to our global client base.”

Some of the topics to be presented in the webinar series will include:

  • “How LC-MS Proteomics is Revolutionizing PBPK Modeling & Simulation” presented by Drs. Amin Rostami (Certara) and Brahim Achour (University of Manchester) on February 18th
  • “How Do We Translate Preclinical and Clinical Research into Drug Labeling?” presented by Dr. Karen Rowland Yeo (Certara) on March 25th
  • “Population Modeling of Modified Risk Tobacco Products” presented by Drs. Bill Poland (Certara) and Jason Pirone (Certara) on April 8th
  • “The Role of Artificial Intelligence in Clinical Trial Transparency” presented by Keith Kleeman (Synchrogenix, a Certara Company) on May 5th

About Certara
Certara is the leading global technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety.

Certara Contact:
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
teresa.bradford@certara.com

Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com

Learn More LinkedIn Twitter Facebook Email